Citadel Advisors »

Karyopharm Therapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Karyopharm Therapeutics (KPTI) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Karyopharm Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Karyopharm Therapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Karyopharm Therapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $602k 92k 6.54
2025-06-30 $961k 223k 4.31
2025-03-31 $828k 221k 3.74

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Tesla Motors Call Option (TSLA)
NVIDIA Corporation Call Option (NVDA)
Apple Call Option (AAPL)
Meta Platforms Cl A Call Option (META)
Microsoft Corporation Call Option (MSFT)
Spdr Gold Tr Gold Shs Call Option (GLD)
Ishares Tr Russell 2000 Etf (IWM)
Amazon Call Option (AMZN)
Strategy Cl A New Call Option (MSTR)
Alphabet Cap Stk Cl A Call Option (GOOGL)
UnitedHealth Call Option (UNH)
Palantir Technologies Cl A Call Option (PLTR)
Netflix Call Option (NFLX)

View all positions for Citadel Advisors

Top funds holding Karyopharm Therapeutics

T. Rowe Price Investment Management
Adage Capital Partners GP
Vanguard Group
Susquehanna International
BlackRock
Affinity Asset Advisors
Catalio Capital Management
Avidity Partners Management
Marshall Wace
CAM Group Holding A/S
Geode Capital Management
Citadel Advisors
Group One Trading
Renaissance Technologies
UBS Group

View all funds holding Karyopharm Therapeutics